trial

Aspirin in Young Psychotic Patients

NCTId NCT02685748
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 60 (actual)
Sponsored by Clinic for Psychiatric Disorders, Dr Laza Lazarevic
Primary completion 2019-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-07-20
Primary completion
2019-12-31
Eligibility
ALL · 18 Years · 28 Years

Interventions & indications

Drugs
AspirinPantoprazole

Sponsors

Clinic for Psychiatric Disorders, Dr Laza LazarevicLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Dragana Pavićević, psychiatristPrincipal Investigator

Sites

1 total
Belgrade, Serbia

Linked catalysts

1
Aspirin in Young Psychotic Patients — primary completion2019-12-31

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE2,PHASE3
Primary Completion Date
2019-12-31
Status
COMPLETED
relationships
The graph out of here
drug
Aspirin
drug
Pantoprazole
drug
lead_sponsor
Clinic for Psychiatric Disorders, Dr Laza Lazarevic
company
collaborator
Stanley Medical Research Institute
company
indication
Psychosis
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
Dragana Pavićević, psychiatrist
person